AnelleO

Executive Summary

AnelleO is a private medical device company headquartered in San Francisco, founded in 2017, that leverages advancements in 3D printing technology to develop novel solutions in women’s health. The company’s initial product focus is intravaginal rings (IVRs) designed for sustained, non-invasive, self-administered delivery of therapeutics over days to months. By utilizing 3D printing, AnelleO aims to enable rapid prototyping and manufacturing flexibility, potentially reducing costs and improving patient compliance compared to traditional IVR production methods. The company operates in the intersection of medical devices and women’s health, addressing unmet needs in contraception, hormone replacement therapy, and treatment of conditions such as vaginal infections and endometriosis. While specific financial details and funding history are not publicly available, AnelleO's innovative platform has the potential to capture significant market share in the expanding women's health sector. The company's profile indicates it is in early stages, with no disclosed commercial products or FDA approvals to date. However, the growing adoption of digital health and personalized medicine could create favorable tailwinds for AnelleO's technology. Key risks include regulatory hurdles, manufacturing scale-up, and competition from established pharmaceutical and device players. Overall, AnelleO represents a promising early-stage opportunity in the drug delivery space, with differentiation rooted in additive manufacturing.

Upcoming Catalysts (preview)

• Q2 2027First FDA 510(k) Clearance for 3D-Printed IVR40% success
• H2 2026Strategic Partnership or Licensing Deal with Major Pharma30% success
• Q3 2026Completion of First-in-Human Clinical Trial for Lead Candidate50% success